Literature DB >> 9672510

Effects of cisapride on QT interval in children.

A Khongphatthanayothin1, J Lane, D Thomas, L Yen, D Chang, B Bubolz.   

Abstract

Recent reports of torsade de pointes and heart block associated with prolonged QT interval in children receiving cisapride raise questions about its safety. We prospectively examined the effects of cisapride on the QT interval in children. Electrocardiography was performed on 30 children before and after cisapride was administered. An additional 71 children underwent electrocardiography only after starting cisapride. The incidence of a corrected QT (QTc) interval > 440 msec or a marked abnormality in T wave morphology was determined in all 101 children. Cisapride significantly lengthened the QTc with a mean increase of 15.5 +/- 4.6 msec (mean +/- SEM, p = 0.002 in the 30 children with baseline electrocardiographs. Twelve of the 101 patients were found to have a QTc > 440 msec, and one had a new prominent notched T wave in all leads. In these 13 (13%) patients with repolarization abnormalities, other factors that might contribute to a long QT were noted in 11 (85%) patients. We conclude that cisapride use in children is associated with a modest increase in QT interval. The incidence of QTc > 440 msec is low. Most children with long QTc have other factors that could compound the effects of cisapride.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9672510     DOI: 10.1016/s0022-3476(98)70177-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.

Authors:  Z Wang; F Xuan; W H Lin; M D Troyer; A Tendolkar; D L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2013-07-16       Impact factor: 2.953

Review 2.  Efficacy and tolerability of cisapride in children.

Authors:  Y Vandenplas; A Benatar; F Cools; A Arana; B Hegar; B Hauser
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

4.  Cisapride improves enteral tolerance in pediatric short-bowel syndrome with dysmotility.

Authors:  Bram P Raphael; Samuel Nurko; Hongyu Jiang; Kristen Hart; Daniel S Kamin; Tom Jaksic; Christopher Duggan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-05       Impact factor: 2.839

5.  Effects of cisapride on QTc interval in term neonates.

Authors:  D S Semama; S Bernardini; S Louf; B Laurent-Atthalin; J B Gouyon
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-01       Impact factor: 5.747

Review 6.  Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review.

Authors:  Denesh K Chitkara; Miranda A L van Tilburg; Nannette Blois-Martin; William E Whitehead
Journal:  Am J Gastroenterol       Date:  2008-01-02       Impact factor: 10.864

7.  Out-of-hospital cardiac arrest and differential risk of cardiac and non-cardiac QT-prolonging drugs in 37 000 cases.

Authors:  Talip E Eroglu; Carlo A Barcella; Marieke T Blom; Grimur H Mohr; Patrick C Souverein; Christian Torp-Pedersen; Fredrik Folke; Mads Wissenberg; Anthonius de Boer; Peter J Schwartz; Gunnar H Gislason; Hanno L Tan
Journal:  Br J Clin Pharmacol       Date:  2021-08-28       Impact factor: 3.716

8.  Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort.

Authors:  Abigail L Coughtrie; Elijah R Behr; Deborah Layton; Vanessa Marshall; A John Camm; Saad A W Shakir
Journal:  BMJ Open       Date:  2017-10-16       Impact factor: 2.692

Review 9.  Ventricular voltage-gated ion channels: Detection, characteristics, mechanisms, and drug safety evaluation.

Authors:  Lulan Chen; Yue He; Xiangdong Wang; Junbo Ge; Hua Li
Journal:  Clin Transl Med       Date:  2021-10

10.  Pharmacological therapy of gastroesophageal reflux in preterm infants.

Authors:  Luigi Corvaglia; Caterina Monari; Silvia Martini; Arianna Aceti; Giacomo Faldella
Journal:  Gastroenterol Res Pract       Date:  2013-06-26       Impact factor: 2.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.